Dr. Bruce Smith, M.D.
Medical Oncology (Medical Oncology Physician)
600 N Wolfe St
Baltimore, MD 21287
Who else practices at this address →
Baltimore city includes primary care (36% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Medical College of Pennsylvania (1991)
- Years since graduation
- 35
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 172
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1991Medical school: Medical College of Pennsylvania
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
MD license D47398
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Johns Hopkins Hospital, the Baltimore, MD
Medical groups
- Johns Hopkins University (2,909 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 172
- Services billed
- 517
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 198 | 35 |
| Established patient office or other outpatient visit, 40-54 minutes | 144 | 62 |
| Bone marrow, smear interpretation | 35 | 34 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 18 | 13 |
| New patient office or other outpatient visit, 60-74 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Sprycel (dasatinib) | 81 |
| Imatinib Mesylate | 51 |
| Allopurinol Other prescribers in Baltimore, MD | 22 |
| Dasatinib | 15 |
| Venclexta (venetoclax) | 15 |
| Tasigna (nilotinib hcl) | 12 |
| Tibsovo (ivosidenib) | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 12 payments worth $14,868 in total to this clinician.
| Servier Pharmaceuticals LLC | $11,568 |
|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $3,300 |
| Consulting Fee | $12,820 |
|---|---|
| Travel and Lodging | $1,961 |
| Food and Beverage | $86.57 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Servier Pharmaceuticals LLC Nov 14, 2025 | Consulting Fee Tibsovo · Oncology | $5,440 |
| Servier Pharmaceuticals LLC Jun 6, 2025 | Consulting Fee Tibsovo · Oncology | $4,080 |
| Takeda Pharmaceuticals U.S.A., Inc. Jan 9, 2025 | Consulting Fee ICLUSIG · ONCOLOGY | $3,300 |
| Servier Pharmaceuticals LLC Jun 6, 2025 | Travel and Lodging Tibsovo · Oncology · travel to Boston, MA | $558 |
| Servier Pharmaceuticals LLC Nov 14, 2025 | Travel and Lodging Tibsovo · Oncology · travel to Boston, MA | $467 |
| Servier Pharmaceuticals LLC Nov 14, 2025 | Travel and Lodging Tibsovo · Oncology · travel to Boston, MA | $441 |
| Servier Pharmaceuticals LLC Jun 6, 2025 | Travel and Lodging Tibsovo · Oncology · travel to Boston, MA | $321 |
| Servier Pharmaceuticals LLC Nov 14, 2025 | Travel and Lodging Tibsovo · Oncology · travel to Boston, MA | $112 |
| Servier Pharmaceuticals LLC Jun 6, 2025 | Travel and Lodging Tibsovo · Oncology · travel to Boston, MA | $62.17 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $10,015 in research payments for these studies, mostly to the institutions running them.
- A phase 3 multi center open label randomized study of oral ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase CML CP previously treated with 2 or more tyrosine kinase inhibitors
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.